What’s happening here?

Those are actually exclamation points.

Nah. Rinse and repeat.

That’s the only good news. Still significant loses and dilution.

It’s like people are reading the 10-Q

Wow. Falling fast.

Higher trades than current price.

Hey! Easy on us snowflakes. We melt.

News out

BATON ROUGE, La., July 02, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, today announces the signing of a work order with leading Contract Research Organization, Theradex Oncology (“Theradex”), detailing the scope to be provided by Theradex for a clinical trial titled, “A Phase 2, Randomized Study of ProscaVax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naïve Patients with Clinically Localized Prostate Cancer Versus and Active Surveillance Strategy.”  The trial, expected to enroll 120 patients, is being hosted at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard University Medical School in Boston, MA.?“We’re extremely pleased to have Theradex once again working with us on the development of ProscaVax,” commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune.  “Theradex is highly sought after for their experience and expertise in advancing promising cancer therapies and we are fortunate to have them on board to provide oversight and the necessary documentation to move this important trial efficiently forward.”
OncBioMune has received all necessary approvals from the host hospital, associated committees and the U.S. Food and Drug Administration to begin the Phase 2 trial.  All requisite information has been submitted to clinicaltrials.gov, with the expectations that the summary of the trial will soon be available for public viewing.

10–Q is out

I second

The keyword is actually treatment. This is for people who already have prostrate cancer. This does not prevent, in the sense people typically associate with vaccines.

From OncBioMune.com

“Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities.”

http://oncbiomune.com/

I think they do.

Options not shares. He has not recently purchased shares.

Would they not have to file a form 4 even if they are exercising options? None of them have done so.

It’s related to their derivative expense. It likely has something to do that the decline of the pps. I don’t have enough financial expertise to comment on how that affects things.

Here is their explanation.

“The Registrant anticipates that there may be a fluctuation in derivative expense which may cause a significant change in results of operations. The Registrant is currently calculating this effect and a reasonable estimate of such change cannot be made as of the date of this filing.”

8K our

Item 7.01 Regulation FD Disclosure

On May 11, 2018, the Institutional Review Board and Scientific Review Committee at the Dana-Farber Cancer Institute approved the clinical trial of ProscaVax™, the Company’s lead immunotherapy product from its platform, at Beth Israel Deaconess Medical Center and Dana-Farber. The Principal Investigator is Rupal Bhatt, MD, PhD with Co-Investigator Glenn Bubley, MD. It is expected that the clinical trial will be enrolling patients in the near future. The clinical trial is titled: “A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/ GM-CSF Vaccine, in Treatment-naive Patients with Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy”.

The 10Q - NT is out.

Like

Most of the post I saw regarding LG suggested they were into toxic funding.

Looks like the volume is drying up. Is the pump over?

Because there have been no trades since 12:58

Believe me, I’d love to see the share price climb. I believe in the science and hope for a better prognosis for patients. I would participate in a raise if offered. Making money off good medicine is the cream on top.

I might be able to let someone slide for misreading a form or not understanding it once or even multiple times. But to continue to do it once corrected is shady.

The repetitive “misreading” of the form.

It is. This is blatant manipulation.

Options aren’t worth money unless they exercise them. Which means paying for the shares at the stated price. I don’t see them doing that. If you do, please let me know.

No shares were purchased. They were granted options.

Well, I guess the pump is on. I wonder if they’ll push it past .02 this time.

I don’t know about that. I just read the form.

Yes. They are options to buy common stock. That is what the derivative is based on.

Sorry, these were not shares they were options.

These shares were not purchased. They were issued as compensation.

I’m having a hard time with the reasoning behind not releasing the subscription numbers. Unless they’re not so good.

It must be truly huge

I use E*TRADE. They never have financials but no problems trading.

80% of Prostate Cancer Patients in OncBioMune Phase 1 Clinical Trial of ProscaVax Show No Disease Progression at the First Post-Therapy Follow-up

November 13, 2017
BATON ROUGE, La., Nov. 13, 2017 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a revenue-stage biopharmaceutical company engaged in the development of a proprietary cancer vaccine technology, targeted cancer therapies and commercialization of a portfolio of products internationally, today releases the latest data updating the progression results at 19 weeks for all 20 patients, who have completed 6 vaccines in their Phase 1 clinical trial of ProscaVax for recurrent prostate cancer patients with increasing prostate specific antigen (PSA). ProscaVax is OncBioMune's novel immunotherapeutic cancer vaccine consisting of a combination of prostate cancer associated PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

All 20 patients enrolled in the trial completed ProscaVax therapy per protocol and have now completed the first follow-up at 19 weeks. 16 of 20 patients (80%) demonstrated stable disease/no prostate cancer progression. Only four patients progressed during ProscaVax therapy (3 PSA progression, 1 radiological progression in the brain).

The safety review confirmed there were no drug-related serious adverse events or dose-limiting toxicities resulting from the vaccine therapy.

OncBioMune is awaiting additional follow-up data related to our previously disclosed study data. This includes additional results on patients beyond the previously reported 12 of 15 patients that received ProscaVax vaccine, who exhibited an increased immune response to PSA as determined with a Lymphocyte Blastogenesis Assay. Also, additional results on the 6 patients vaccinated after OncBioMune previously reported that 9 of 14 patients who received six ProscaVax vaccinations demonstrated increased PSA doubling times. Additional follow-up will provide longer follow-up intervals for the last six patients who completed the vaccine therapy.

“All the data to date is consistent with previous study data showing ProscaVax elicits immune responses to fight tumor growth in prostate cancer,” said Dr. Jonathan Head, Chief Executive Officer at OncBioMune. “We are impressed that 80 percent of the patients treated with ProscaVax demonstrated stable disease. We look forward to continuing to follow the patients in this study to collect additional data and also to conducting a larger study to further validate the therapeutic benefit of our vaccine platform technology.”

I would guess they’re not doing very well at this point. It will be interesting to see how sales go in the US. I’m not expecting much. I don’t see how they will be able to stand up to SPORT if the reviews continue to be as positive as the initial reviews from Nicholson.

Senhance just got approved. Stock doubling.